ContraFect Co. (NASDAQ:CFRX – Get Rating) – Equities research analysts at SVB Leerink lowered their Q2 2022 earnings per share (EPS) estimates for shares of ContraFect in a research note issued to investors on Monday, May 16th. SVB Leerink analyst R. Ruiz now anticipates that the biotechnology company will post earnings of ($0.27) per share for the quarter, down from their prior estimate of ($0.23). SVB Leerink has a “Outperform” rating and a $9.00 price objective on the stock. SVB Leerink also issued estimates for ContraFect’s Q4 2022 earnings at ($0.12) EPS, FY2022 earnings at ($1.09) EPS, FY2023 earnings at ($1.05) EPS and FY2025 earnings at $2.00 EPS.
Separately, StockNews.com started coverage on shares of ContraFect in a research note on Friday, May 13th. They issued a “sell” rating for the company.
ContraFect (NASDAQ:CFRX – Get Rating) last issued its earnings results on Monday, May 16th. The biotechnology company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.20).
Hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of ContraFect by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock worth $1,486,000 after purchasing an additional 4,948 shares in the last quarter. State Street Corp grew its holdings in shares of ContraFect by 33.5% during the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after buying an additional 32,563 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of ContraFect by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock worth $5,664,000 after purchasing an additional 11,064 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in ContraFect by 62.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 43,564 shares in the last quarter. Finally, White Pine Capital LLC grew its holdings in shares of ContraFect by 15.3% in the first quarter. White Pine Capital LLC now owns 356,217 shares of the biotechnology company’s stock valued at $1,300,000 after purchasing an additional 47,354 shares during the period. Institutional investors and hedge funds own 59.39% of the company’s stock.
ContraFect Company Profile (Get Rating)
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia.
- Get a free copy of the StockNews.com research report on ContraFect (CFRX)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.